Literature DB >> 5882485

[New contents in Ruta graveolens L. 3. Studies in the field of the chemistry of natural substances].

J Reisch.   

Abstract

Entities:  

Mesh：

Year:  1965        PMID： 5882485

Source DB:  PubMed          Journal:  Pharmazie        ISSN： 0031-7144            Impact factor:   1.267


× No keyword cloud information.
  15 in total

1.  Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.

Authors:  Renier Myburgh; Jonathan D Kiefer; Norman F Russkamp; Chiara F Magnani; Nicolás Nuñez; Alexander Simonis; Surema Pfister; C Matthias Wilk; Donal McHugh; Juliane Friemel; Antonia M Müller; Burkhard Becher; Christian Münz; Maries van den Broek; Dario Neri; Markus G Manz
Journal:  Leukemia       Date:  2020-05-01       Impact factor: 11.528

2.  Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds.

Authors:  David K Y Zhang; Alexander S Cheung; David J Mooney
Journal:  Nat Protoc       Date:  2020-01-13       Impact factor: 13.491

3.  IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor.

Authors:  Yuying Liu; Nannan Zhou; Li Zhou; Jing Wang; Yabo Zhou; Tianzhen Zhang; Yi Fang; Jinwei Deng; Yunfeng Gao; Xiaoyu Liang; Jiadi Lv; Zhenfeng Wang; Jing Xie; Yuanbo Xue; Huafeng Zhang; Jingwei Ma; Ke Tang; Yiliang Fang; Feiran Cheng; Chengjuan Zhang; Bing Dong; Yuzhou Zhao; Peng Yuan; Quanli Gao; Haizeng Zhang; F Xiao-Feng Qin; Bo Huang
Journal:  Nat Immunol       Date:  2021-01-11       Impact factor: 25.606

Review 4.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

5.  Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.

Authors:  Shunsuke Goto; Yukimi Sakoda; Keishi Adachi; Yoshitaka Sekido; Seiji Yano; Masatoshi Eto; Koji Tamada
Journal:  Cancer Immunol Immunother       Date:  2021-02-08       Impact factor: 6.968

Review 6.  Value and affordability of CAR T-cell therapy in the United States.

Authors:  Salvatore Fiorenza; David S Ritchie; Scott D Ramsey; Cameron J Turtle; Joshua A Roth
Journal:  Bone Marrow Transplant       Date:  2020-05-30       Impact factor: 5.483

Review 7.  Novel Therapies in the Treatment of Hodgkin Lymphoma.

Authors:  Xavier Andrade-Gonzalez; Stephen M Ansell
Journal:  Curr Treat Options Oncol       Date:  2021-03-23

8.  Challenges of Cellular Therapy During the COVID-19 Pandemic.

Authors:  Kamal Kant Sahu; Sikander Ailawadhi; Natalie Malvik; Jan Cerny
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.

Authors:  Muhammad Sadeqi Nezhad; Meghdad Abdollahpour-Alitappeh; Behzad Rezaei; Mahboubeh Yazdanifar; Alexander Marcus Seifalian
Journal:  Pharm Res       Date:  2021-06-10       Impact factor: 4.200

Review 10.  Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.

Authors:  Coen J Lap; Samah Nassereddine; Kieron Dunleavy
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.